WO2022103983A3 - Composés de fluorénylméthyloxycarbonyle et de fluorénylméthylaminocarbonyle, conjugués protéines associés et méthodes d'utilisation - Google Patents

Composés de fluorénylméthyloxycarbonyle et de fluorénylméthylaminocarbonyle, conjugués protéines associés et méthodes d'utilisation Download PDF

Info

Publication number
WO2022103983A3
WO2022103983A3 PCT/US2021/059014 US2021059014W WO2022103983A3 WO 2022103983 A3 WO2022103983 A3 WO 2022103983A3 US 2021059014 W US2021059014 W US 2021059014W WO 2022103983 A3 WO2022103983 A3 WO 2022103983A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
methods
fluorenylmethylaminocarbonyl
fluorenylmethyloxycarbonyl
protein conjugates
Prior art date
Application number
PCT/US2021/059014
Other languages
English (en)
Other versions
WO2022103983A9 (fr
WO2022103983A2 (fr
Inventor
Krishna BAJJURI
Original Assignee
Sutro Biopharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sutro Biopharma, Inc. filed Critical Sutro Biopharma, Inc.
Publication of WO2022103983A2 publication Critical patent/WO2022103983A2/fr
Publication of WO2022103983A9 publication Critical patent/WO2022103983A9/fr
Publication of WO2022103983A3 publication Critical patent/WO2022103983A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C08G65/332—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
    • C08G65/3324—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof cyclic
    • C08G65/3326—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof cyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33303—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing amino group
    • C08G65/3331—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing amino group cyclic
    • C08G65/33313—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing amino group cyclic aromatic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33396—Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Polyethers (AREA)

Abstract

La présente invention concerne des composés, des produits conjugués associés, des méthodes et des compositions pharmaceutiques destinées à une utilisation thérapeutique ou diagnostique.
PCT/US2021/059014 2020-11-11 2021-11-11 Composés de fluorénylméthyloxycarbonyle et de fluorénylméthylaminocarbonyle, conjugués protéines associés et méthodes d'utilisation WO2022103983A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063112536P 2020-11-11 2020-11-11
US63/112,536 2020-11-11

Publications (3)

Publication Number Publication Date
WO2022103983A2 WO2022103983A2 (fr) 2022-05-19
WO2022103983A9 WO2022103983A9 (fr) 2022-06-09
WO2022103983A3 true WO2022103983A3 (fr) 2022-06-30

Family

ID=78825094

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/059014 WO2022103983A2 (fr) 2020-11-11 2021-11-11 Composés de fluorénylméthyloxycarbonyle et de fluorénylméthylaminocarbonyle, conjugués protéines associés et méthodes d'utilisation

Country Status (1)

Country Link
WO (1) WO2022103983A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060293499A1 (en) * 2005-06-16 2006-12-28 Bentley Michael D Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
WO2008082669A2 (fr) * 2006-12-27 2008-07-10 Nektar Therapeutics Al, Corporation Conjugués polymère-facteur viii et facteur von willebrand comprenant une liaison dégradable
US10220020B2 (en) * 2010-12-23 2019-03-05 Nektar Therapeutics Polymer-des-ethyl sunitinib conjugates
WO2021067458A1 (fr) * 2019-09-30 2021-04-08 Beijing Xuanyi Pharmasciences Co., Ltd. Conjugués protéine-macromolécule et leurs méthodes d'utilisation

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4753894A (en) 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
HU219537B (hu) 1991-03-06 2001-05-28 Merck Patent Gmbh. Humanizált és kiméra monoklonális antitestek, azokat tartalmazó gyógyászati készítmények, az antitesteket kódoló szekvenciát tartalmazó expressziós vektorok, valamint eljárás az antitestek előállítására
CA2118130A1 (fr) 1992-04-14 1993-10-28 Jean M. J. Frechet Macromolecules composees de polymeres dendritiques et methode de production
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
GB9401182D0 (en) 1994-01-21 1994-03-16 Inst Of Cancer The Research Antibodies to EGF receptor and their antitumour effect
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
AU6267896A (en) 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO2000034337A1 (fr) 1998-12-10 2000-06-15 Tsukuba Research Laboratory, Toagosei Co., Ltd. Anticorps monoclonaux humanises luttant contre un facteur de croissance de cellules endotheliales vasculaires
US7129332B2 (en) 2000-02-25 2006-10-31 The United States Of America As Represented By The Department Of Health And Human Services Anti-EGFRvIII scFvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof
JP2003533987A (ja) 2000-05-19 2003-11-18 イス ケミカル カンパニー リミテッド 表皮成長因子収容体に対するヒト化抗体
CZ200438A3 (cs) 2001-06-13 2004-06-16 Genmab A/S Název neuveden
CA2466027C (fr) 2001-11-07 2013-01-08 Nektar Therapeutics Al, Corporation Polymeres ramifies et conjugues associes
DE10156482A1 (de) 2001-11-12 2003-05-28 Gundram Jung Bispezifisches Antikörper-Molekül
US7375078B2 (en) 2004-02-23 2008-05-20 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
ES2379526T3 (es) 2004-04-30 2012-04-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticuerpo anti-TfR
US8431558B2 (en) 2004-11-01 2013-04-30 The Regents Of The University Of California Compositions and methods for modification of biomolecules
US8519122B2 (en) 2010-02-12 2013-08-27 The Regents Of The University Of California Compositions and methods for modification of biomolecules
CN103153927B (zh) 2010-04-27 2017-02-15 西纳福克斯股份有限公司 稠合的环辛炔化合物及其在无金属点击反应中的应用
US9145361B2 (en) 2011-03-25 2015-09-29 Life Technologies Corporation SDP-containing heterobifunctional agents
US20130251783A1 (en) 2011-09-14 2013-09-26 Universitat Heidelberg Liposomes containing permeation enhancers for oral drug delivery
WO2013092998A1 (fr) 2011-12-23 2013-06-27 Innate Pharma Conjugaison enzymatique d'anticorps
MX2018009085A (es) 2016-01-27 2019-05-09 Sutro Biopharma Inc Conjugados de anticuerpos anti-cd74, composiciones que comprenden conjugados de anticuerpos anti-cd74 y metodos de uso de congujados de anticuerpos anti-cd74.
BR112020005212A2 (pt) 2017-09-18 2020-09-15 Sutro Biopharma, Inc. conjugado de anticorpo, kit, composição farmacêutica, e, métodos de tratamento ou prevenção e de diagnóstico de uma doença ou condição.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060293499A1 (en) * 2005-06-16 2006-12-28 Bentley Michael D Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
WO2008082669A2 (fr) * 2006-12-27 2008-07-10 Nektar Therapeutics Al, Corporation Conjugués polymère-facteur viii et facteur von willebrand comprenant une liaison dégradable
US10220020B2 (en) * 2010-12-23 2019-03-05 Nektar Therapeutics Polymer-des-ethyl sunitinib conjugates
WO2021067458A1 (fr) * 2019-09-30 2021-04-08 Beijing Xuanyi Pharmasciences Co., Ltd. Conjugués protéine-macromolécule et leurs méthodes d'utilisation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHAD J. PICKENS ET AL: "Practical Considerations, Challenges, and Limitations of Bioconjugation via Azide?Alkyne Cycloaddition", BIOCONJUGATE CHEMISTRY, vol. 29, no. 3, 21 March 2018 (2018-03-21), US, pages 686 - 701, XP055585087, ISSN: 1043-1802, DOI: 10.1021/acs.bioconjchem.7b00633 *
HAIM TSUBERY ET AL: "Prolonging the Action of Protein and Peptide Drugs by a Novel Approach of Reversible Polyethylene Glycol Modification", 20040910, vol. 279, no. 37, 10 September 2004 (2004-09-10), pages 38118 - 38124, XP002336480 *
REMON VAN GEEL ET AL: "Chemoenzymatic Conjugation of Toxic Payloads to the Globally Conserved N-Glycan of Native mAbs Provides Homogeneous and Highly Efficacious Antibody–Drug Conjugates", BIOCONJUGATE CHEMISTRY, vol. 26, no. 11, 10 June 2015 (2015-06-10), US, pages 2233 - 2242, XP055249394, ISSN: 1043-1802, DOI: 10.1021/acs.bioconjchem.5b00224 *

Also Published As

Publication number Publication date
WO2022103983A9 (fr) 2022-06-09
WO2022103983A2 (fr) 2022-05-19

Similar Documents

Publication Publication Date Title
EP4241847A3 (fr) Molécule de liaison de ciblage cellulaire améliorée
EP4316524A3 (fr) Derives de camptothecine
WO2011157741A3 (fr) Conjugués anticorps humain-médicament contre le facteur tissulaire
EP4025257A4 (fr) Conjugué anticorps-médicament comprenant un anticorps contre le ror1 humain, et son utilisation
WO2019136180A3 (fr) Molécules d'acide nucléique hétéroduplex et leurs utilisations
WO2020056198A3 (fr) Composés de benzazépine substitués, conjugués et leurs utilisations
EP4306538A3 (fr) Conjugués d'oligonucléotides peptidiques
EP2298813A3 (fr) Anticorps monoclonaux anti-TRKB et utilisations de ceux-ci
WO2016172657A3 (fr) Agents thérapeutiques de glycanes et procédés de traitement
EP2374480A3 (fr) Conjugués de ligands multi-médicaments
CY1119968T1 (el) Συνθεσεις καινοτομων καλλυντικων και/ή φαρμακευτικων προϊοντων και χρησεις αυτων
BR112012006252A2 (pt) "formas cristalinas de abt-263 e solvatos para o uso no tratamento de doenças relacionadas á proteína bcl-2".
EA200602047A1 (ru) Сульфонилэтилфосфородиамидаты, предназначенные для применения при лечении рака
EP3381445A3 (fr) Formulation aqueuse d'anticorps stabilisée par des antioxydants pour administration parentérale
WO2019241672A3 (fr) Variants de piline comp glycosylés, leurs procédés de fabrication et leurs utilisations
EP3915991A4 (fr) Dérivé de pyrrolopyrimidine et composition pharmaceutique pour la prévention ou le traitement d'une maladie liée à la protéine kinase le comprenant en tant que principe actif
EP3978029A4 (fr) Acide nucléique, composition et conjugué pharmaceutiques, leur procédé de préparation et leur utilisation
EP4101860A4 (fr) Dérivé d'acide hyaluronique, composition pharmaceutique et conjugué médicament-dérivé d'acide hyaluronique-
MX2021003349A (es) Proteina de fusion glp1-fc y conjugado de la misma.
EP4066861A4 (fr) Médicament conjugué de polyéthylène glycol, son procédé de préparation et son utilisation
WO2019200314A3 (fr) Analogues d'hinokitiol, procédés de préparation et compositions pharmaceutiques de ceux-ci
WO2022103983A3 (fr) Composés de fluorénylméthyloxycarbonyle et de fluorénylméthylaminocarbonyle, conjugués protéines associés et méthodes d'utilisation
WO2006032525A3 (fr) Therapie combinatoire pour le traitement du cancer
EP3974533A4 (fr) Acide nucléique, composition pharmaceutique, conjugué, procédé de préparation et utilisation
WO2007104768A3 (fr) Conjugués de protéines di-polymères et leurs procédés d'élaboration

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21820770

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21820770

Country of ref document: EP

Kind code of ref document: A2